Related Experiment Video
Updated: Aug 26, 2026
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
[VEGF antisense oligonucleotide inhibits the expression of vascular endothelial growth factor in human leukemic cell
Ling Zhang1, Zhi-guang Tu, Wen-li Feng
1Faculty of Laboratory Medicine, Chongqing University of Medical Sciences, Chongqing 400016, China.
Objective:
To explore the effects of vascular endothelial growth factor (VEGF) antisense phosphorothioated oligodeoxynucleotide (AS-ODN) on the expression of VEGF in human leukemic cell lines (HL-60 and K562 cells).
Methods:
The levels of VEGF mRNA and protein in leukemic cells incubated with VEGF AS-ODN were measured by RT-PCR, immunohistochemistry assay and ELISA. MTT test was used to examine the influence of the culture supernatant (CS) of VEGF AS-ODN treated leukemic cells on the proliferation of human umbilical vein endothelial cells (ECV304).
Results:
After leukemic cells were treated with different concentrations (2.5 approximately 15.0 micro mol/L) of VEGF AS-ODN for 24 h, VEGF mRNA level in the cells decreased remarkably in a concentration dependent manner, no change was found in the VEGF missense ODN treated cells (MS-ODN). When the leukemic cells were treated with 5 micro mol/L VEGF AS-ODN for 24 h, VEGF protein level decreased greatly both in the cells and in the CS; and the proliferation stimulating effect of the treated CS on the ECV304 cells reduced. Meanwhile, there was no obvious change in VEGF protein and its effect in the VEGF MS-ODN treated group.
Conclusion:
VEGF AS-ODN could inhibit VEGF expression in human leukemic cell lines in vitro.
Insights
Vascular endothelial growth factor (VEGF) antisense phosphorothioated oligodeoxynucleotide (AS-ODN) effectively inhibits VEGF expression in human leukemia cell lines. This suggests AS-ODN as a potential therapeutic strategy for leukemia by targeting VEGF signaling.
Area of Science:
- Molecular Biology
- Cancer Research
- Oligonucleotide Therapeutics
Context:
- Vascular Endothelial Growth Factor (VEGF) plays a crucial role in angiogenesis and tumor growth.
- Leukemic cell lines HL-60 and K562 are utilized to study VEGF expression.
- Antisense oligodeoxynucleotides (AS-ODN) are investigated as a targeted gene silencing approach.
Purpose:
- To investigate the inhibitory effect of VEGF antisense phosphorothioated oligodeoxynucleotide (AS-ODN) on VEGF expression in human leukemic cells.
- To assess the impact of VEGF AS-ODN on VEGF mRNA and protein levels.
- To evaluate the effect of VEGF AS-ODN on the proliferation of human umbilical vein endothelial cells.
Summary:
- Treatment of HL-60 and K562 cells with VEGF AS-ODN resulted in a dose-dependent decrease in VEGF mRNA levels.
- VEGF protein expression in leukemic cells and their culture supernatant was significantly reduced by VEGF AS-ODN.
- The proliferation-stimulating effect of the treated supernatant on endothelial cells was diminished, unlike with missense ODN controls.
Impact:
- VEGF AS-ODN demonstrates potent inhibition of VEGF expression in vitro, highlighting its potential as a therapeutic agent for leukemia.
- The findings support the role of VEGF in leukemic cell biology and suggest targeting VEGF signaling as a viable treatment strategy.
- This study provides a foundation for further research into oligonucleotide-based therapies for hematological malignancies.
More Related Videos
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:10Mechanism of Angiogenesis